People with type 2 diabetes who had been taking GLP-1 receptor agonists appear to have better outcomes if they develop necrotizing soft tissue infections, a group of infections associated with high mortality and morbidity. A retrospective database analysis published in BMC Endocrine Disorders found that patients who had used these drugs within six months before their necrotizing soft tissue infection diagnosis had significantly lower mortality at both three and six months of follow-up.
The study included 16,792 patients with type 2 diabetes who had used a GLP-1 receptor agonist within six months before their necrotizing soft tissue infection diagnosis. Patients younger than 18 and those with NSTI diagnoses more than 20 years earlier were excluded. Because patients who take these medications may differ systematically from those who do not, the researchers used propensity score matching to balance baseline characteristics between groups. After matching, 1,099 patients remained in each group, allowing a more direct comparison of outcomes.
The matched analysis showed that GLP-1 receptor agonist use was associated with lower all-cause mortality, with a hazard ratio of 0.49 (95% confidence interval 0.30 to 0.82) at three months and 0.53 (95% confidence interval 0.34 to 0.82) at six months of follow-up. In other words, recent users had roughly half the hazard of death over these periods compared with matched non-users, though the wide confidence intervals reflect uncertainty in these estimates from a single retrospective dataset.
Beyond survival, the drug users also showed a lower risk of short-term acute respiratory distress syndrome, with an odds ratio of 0.54 (95% confidence interval 0.30 to 0.96). Amputation risk was significantly reduced as well, with odds ratios of 0.69 (95% confidence interval 0.49 to 0.97) at three months and 0.67 (95% confidence interval 0.48 to 0.93) at six months. However, no significant differences were observed for the other secondary outcomes examined, which included major adverse cardiovascular events, acute kidney injury, and the need for blood transfusion.
The authors emphasize that the association between GLP-1 receptor agonist use and outcomes in these patients had remained unclear until now, and that the observed survival benefit should be interpreted with caution.
Indeed, the study’s conclusion states plainly that while GLP-1 receptor agonist therapy was associated with a lower risk of mortality among patients with type 2 diabetes who developed necrotizing soft tissue infections, residual confounding cannot be excluded, and causal relationships cannot be established from this retrospective design. The authors note that residual confounding cannot be excluded, meaning that patients who use these medications may differ from non-users in ways the propensity score matching could not fully capture, and that causal relationships cannot be established from this retrospective study.
The findings are therefore a signal for further investigation rather than a treatment recommendation. The authors call for additional studies to clarify the role of GLP-1 receptor agonists in predicting clinical outcomes in this high-risk population.
Subject of Research: Retrospective study of GLP-1 receptor agonist use and outcomes in necrotizing soft tissue infections among patients with type 2 diabetes
Article Title: Association of GLP-1 receptor agonist use with clinical outcomes in necrotizing soft tissue infections among patients with type 2 diabetes
Article References: Lai, Y.-H., Chang, Y., Wong, C.-E., Huang, C.-Y., Lee, J.-S., Huang, Y.-T., Khor, W.-T., & Perng, P.-S. (2026). Association of GLP-1 receptor agonist use with clinical outcomes in necrotizing soft tissue infections among patients with type 2 diabetes. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02673-5
Image Credits: AI Generated
DOI: 10.1186/s12902-026-02673-5
Keywords: GLP-1 receptor agonists, type 2 diabetes, necrotizing soft tissue infections, mortality, propensity score matching, amputation, acute respiratory distress syndrome, retrospective study, BMC Endocrine Disorders, residual confounding, Association, GLP-1
News Source: Ophelia Keating. (October 29, 2026). GLP-1 Drug Use Linked to Better Survival in Diabetic Flesh-Eating Infections. Scienmag.
